Abstract
Orexin A and B (also named hypocretin 1 and 2) are 33 and 28 amino acid-containing neuropeptides, respectively, derived from prepro-orexin (prepro-hypocretin) which is localized in the lateral and perifonical areas of the hypothalamus. Two G-protein coupled receptor subtypes, OX1 and OX2, were identified. Orexin-containing fibers and OX receptors are widely distributed in the central nervous system. Orexins have been implicated in the arousal, rewarding, energy homeostasis, autonomic central control and antinociceptive systems. Subtype-selective peptide agonists and antagonists and non-peptide antagonists, but not non-peptide agonists, have been developed. This review summarizes the studies investigating the antinociceptive effects of orexins in various animal models of pain, including trigeminovascular pain, and their cellular mechanisms. Orexins are antinociceptive at both spinal and supraspinal levels. The antinociceptive effect of orexin A is comparable to opioids but orexin B is less or not effective. This effect is opioid-independent and mainly mediated through OX1 receptors. Some animal studies suggest that endogenous orexins may be released during postoperative and inflammatory, but not acute, pain states, or during some stress conditions, which may contribute to stress-induced analgesia. Purinergic P2X and glycine receptors are proposed to be involved in orexin-induced spinal antinociception. The supraspinal sites of actions might involve the posterior hypothalamus, which contributes to the trigeminovascular nociception, and the ventrolateral periaqueductal gray, which mediates descending pain inhibition. Endocannobinoids and nociceptin/orphanin FQ were found to interplay with orexins in nocicpetive processing. Further studies are required to elucidate the receptor subtype-specific mechanism(s) and clinical implications of orexin-induced antinociception.
Keywords: Orexins/Hypocretins, OX1/OX2 receptors, Nociceptin/Orphanin FQ, Pain, Endocannabinoids, Migraine, Cluster headache
Current Pharmaceutical Design
Title: Orexins/Hypocretins: Pain Regulation and Cellular Actions
Volume: 16 Issue: 28
Author(s): Lih-Chu Chiou, Hsin-Jung Lee, Yu-Cheng Ho, Shih-Pin Chen, Yan-Yu Liao, Chia-Hau Ma, Pi-Chuan Fan, Jong-Ling Fuh and Shuu-Jiun Wang
Affiliation:
Keywords: Orexins/Hypocretins, OX1/OX2 receptors, Nociceptin/Orphanin FQ, Pain, Endocannabinoids, Migraine, Cluster headache
Abstract: Orexin A and B (also named hypocretin 1 and 2) are 33 and 28 amino acid-containing neuropeptides, respectively, derived from prepro-orexin (prepro-hypocretin) which is localized in the lateral and perifonical areas of the hypothalamus. Two G-protein coupled receptor subtypes, OX1 and OX2, were identified. Orexin-containing fibers and OX receptors are widely distributed in the central nervous system. Orexins have been implicated in the arousal, rewarding, energy homeostasis, autonomic central control and antinociceptive systems. Subtype-selective peptide agonists and antagonists and non-peptide antagonists, but not non-peptide agonists, have been developed. This review summarizes the studies investigating the antinociceptive effects of orexins in various animal models of pain, including trigeminovascular pain, and their cellular mechanisms. Orexins are antinociceptive at both spinal and supraspinal levels. The antinociceptive effect of orexin A is comparable to opioids but orexin B is less or not effective. This effect is opioid-independent and mainly mediated through OX1 receptors. Some animal studies suggest that endogenous orexins may be released during postoperative and inflammatory, but not acute, pain states, or during some stress conditions, which may contribute to stress-induced analgesia. Purinergic P2X and glycine receptors are proposed to be involved in orexin-induced spinal antinociception. The supraspinal sites of actions might involve the posterior hypothalamus, which contributes to the trigeminovascular nociception, and the ventrolateral periaqueductal gray, which mediates descending pain inhibition. Endocannobinoids and nociceptin/orphanin FQ were found to interplay with orexins in nocicpetive processing. Further studies are required to elucidate the receptor subtype-specific mechanism(s) and clinical implications of orexin-induced antinociception.
Export Options
About this article
Cite this article as:
Chiou Lih-Chu, Lee Hsin-Jung, Ho Yu-Cheng, Chen Shih-Pin, Liao Yan-Yu, Ma Chia-Hau, Fan Pi-Chuan, Fuh Jong-Ling and Wang Shuu-Jiun, Orexins/Hypocretins: Pain Regulation and Cellular Actions, Current Pharmaceutical Design 2010; 16 (28) . https://dx.doi.org/10.2174/138161210793292483
DOI https://dx.doi.org/10.2174/138161210793292483 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabotropic Glutamate Receptor Dependent Cortical Plasticity in Chronic Pain
Current Neuropharmacology Is Mental Practice an Effective Adjunct Therapeutic Strategy for Upper Limb Motor Restoration After Stroke? A Systematic Review and Meta- Analysis
CNS & Neurological Disorders - Drug Targets Dependence of Cell Survival on Correlative Activities of Xanthine Oxidase and Dihydopyrimidine Dehydrogenase in Human Brain-Derived Cell Culture
Central Nervous System Agents in Medicinal Chemistry Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart
Medicinal Chemistry Riboregulators and Metabolic Disorders: Getting Closer Towards Understanding the Pathogenesis of Diabetes Mellitus?
Current Molecular Medicine Oxidative Stress and Skeletal Muscle Dysfunction with Aging
Current Aging Science Antiepileptic Drug-Induced Hypersensitivity Syndrome Reactions
Current Drug Safety Mitochondria: A Connecting Link in the Major Depressive Disorder Jigsaw
Current Neuropharmacology The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery
Current Drug Targets Free Interval Duration: Clinical Evidence of the Primary Role of Excitement in Bipolar Disorder
Current Neuropharmacology Strategies to Improve Bioavailability and <i>In Vivo</i> Efficacy of the Endogenous Opioid Peptides Endomorphin-1 and Endomorphin-2
Current Topics in Medicinal Chemistry Insulin Growth Factor-I Promotes Functional Recovery After a Focal Lesion in the Dentate Gyrus
CNS & Neurological Disorders - Drug Targets Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Thematic Issue: Emerging Targets for Stimulant Use Disorders: Where To Invest In An Era Of Constrained Resources?)
CNS & Neurological Disorders - Drug Targets An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
Current Pharmaceutical Design Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets The Contribution of Formyl Peptide Receptor Dysfunction to the Course of Neuroinflammation: A Potential Role in the Brain Pathology
Current Neuropharmacology The Microbiota and Gut-Brain Axis: Contributions to the Immunopathogenesis of Schizophrenia
Current Pharmaceutical Design Editorial (Hot Topic: The State of the Art in Diagnosis and Treatment of Soft Bipolar Disorders)
Current Psychiatry Reviews